This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
by Zacks Equity Research
The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021. Shares rise.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 8.70% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2020 results.
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
by Zacks Equity Research
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening
by Benjamin Rains
We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.90% and -1.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 2.17% and -23.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Ocular Therapeutix
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
by Zacks Equity Research
The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.